Noriyuki Masaki1,2,3,4, Nathaniel F Wu1,5, Yusuke Aoki1,4, Jun Yamamoto1,4, Jun Miyazaki3, Robert M Hoffman6,4. 1. AntiCancer Inc, San Diego, CA, U.S.A. 2. Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan. 3. Department of Urology, School of Medicine, International University of Health and Welfare, Narita, Japan. 4. Department of Surgery, University of California, San Diego, CA, U.S.A. 5. Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, U.S.A. 6. AntiCancer Inc, San Diego, CA, U.S.A.; all@anticancer.com.
Abstract
BACKGROUND/AIM: Primary osteosarcoma of the mammary gland is a very rare disease, accounting for less than 1% of all mammary malignancies. There is no established first-line treatment and the prognosis is poor compared to normal breast cancer. We previously established the first patient tumor-derived animal model of this disease, grown subcutaneously in nude mice. In the present study, we established a patient derived orthotopic xenograft (PDOX) model of osteosarcoma of the breast and investigated the efficacy of cisplatinum (CDDP) and eribulin (ERB). MATERIALS AND METHODS: PDOX models of primary osteosarcoma of the breast were divided into 3 groups (5-6 mice per group): untreated control; CDDP treatment; ERB treatment. The tumor volume in the 3 groups was compared after 2 weeks. RESULTS: There were significant differences between control and CDDP, and control and ERB (p=0.036, 0.046, respectively). However, there was no significant difference between CDDP and ERB (p=0.964). CONCLUSION: CDDP and ERB are candidates for first-line clinical therapy of primary osteosarcoma of the breast.
BACKGROUND/AIM: Primary osteosarcoma of the mammary gland is a very rare disease, accounting for less than 1% of all mammary malignancies. There is no established first-line treatment and the prognosis is poor compared to normal breast cancer. We previously established the first patient tumor-derived animal model of this disease, grown subcutaneously in nude mice. In the present study, we established a patient derived orthotopic xenograft (PDOX) model of osteosarcoma of the breast and investigated the efficacy of cisplatinum (CDDP) and eribulin (ERB). MATERIALS AND METHODS: PDOX models of primary osteosarcoma of the breast were divided into 3 groups (5-6 mice per group): untreated control; CDDP treatment; ERB treatment. The tumor volume in the 3 groups was compared after 2 weeks. RESULTS: There were significant differences between control and CDDP, and control and ERB (p=0.036, 0.046, respectively). However, there was no significant difference between CDDP and ERB (p=0.964). CONCLUSION: CDDP and ERB are candidates for first-line clinical therapy of primary osteosarcoma of the breast.
Authors: Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman Journal: Lancet Date: 2018-01-31 Impact factor: 79.321
Authors: Nathaniel F Wu; Justin Wu; Jun Yamamoto; Yusuke Aoki; Chihiro Hozumi; Michael Bouvet; Robert M Hoffman Journal: In Vivo Date: 2021 Jul-Aug Impact factor: 2.155
Authors: Gabriel Vorobiof; Gangaram Hariparsad; Woolf Freinkel; Harry Said; Daniel A Vorobiof Journal: Breast J Date: 2003 May-Jun Impact factor: 2.431
Authors: Alannah Smrke; Peter M Anderson; Ashish Gulia; Spyridon Gennatas; Paul H Huang; Robin L Jones Journal: Cells Date: 2021-01-15 Impact factor: 6.600